These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28653113)

  • 1. Association of soluble ST2 with functional capacity in outpatients with heart failure.
    Yucel O; Gul I; Zararsiz A; Demirpence O; Yucel H; Cinar Z; Zorlu A; Yilmaz MB
    Herz; 2018 Aug; 43(5):455-460. PubMed ID: 28653113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study.
    Bahuleyan CG; Alummoottil GK; Abdullakutty J; Lordson AJ; Babu S; Krishnakumar VV; Pillai AM; Abraham G; Dilip MN
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S79-S84. PubMed ID: 30122243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
    Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
    Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytopenia is associated with poor NYHA functional class in chronic heart failure patients with reduced ejection fraction.
    Yücel H; Refiker Ege M; Zorlu A; Kaya H; Beton O; Güngör H; Acar G; Temizhan A; Çavuşoğlu Y; Zoghi M; Eren M; Ural D; Yılmaz MB
    Turk Kardiyol Dern Ars; 2015 Jul; 43(5):427-33. PubMed ID: 26148074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ST2 in heart failure with preserved and reduced ejection fraction.
    Najjar E; Faxén UL; Hage C; Donal E; Daubert JC; Linde C; Lund LH
    Scand Cardiovasc J; 2019 Feb; 53(1):21-27. PubMed ID: 30776920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic value of combining serum soluble ST2 and interleukin-33 for heart failure patients with preserved left ventricular ejection fraction].
    Luo NS; Zhang HF; Liu PM; Lin YQ; Huang TC; Yang Y; Wang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):198-203. PubMed ID: 28316175
    [No Abstract]   [Full Text] [Related]  

  • 7. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.
    Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A;
    J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure.
    Bayes-Genis A; Pascual-Figal D; Januzzi JL; Maisel A; Casas T; Valdés Chávarri M; Ordóñez-Llanos J
    Rev Esp Cardiol; 2010 Oct; 63(10):1171-8. PubMed ID: 20875357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble ST2 protein and hospitalizations due to worsening chronic heart failure during a one-year follow-up in a population with reduced ejection fraction.
    Wojtczak-Soska K; Sakowicz A; Pietrucha T; Janikowski K; Lelonek M
    Adv Clin Exp Med; 2017 Sep; 26(6):931-938. PubMed ID: 29068593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.
    Felker GM; Fiuzat M; Thompson V; Shaw LK; Neely ML; Adams KF; Whellan DJ; Donahue MP; Ahmad T; Kitzman DW; Piña IL; Zannad F; Kraus WE; O'Connor CM
    Circ Heart Fail; 2013 Nov; 6(6):1172-9. PubMed ID: 24103327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
    Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
    J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients.
    Wang YC; Yu CC; Chiu FC; Tsai CT; Lai LP; Hwang JJ; Lin JL
    J Card Fail; 2013 Mar; 19(3):163-8. PubMed ID: 23482076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart Failure.
    Muksinova MD; Narusov OY; Sychev AV; Sharf TV; Masenko VP; Tereshchenko SN; Skvortsov AA
    Kardiologiia; 2023 Dec; 63(12):87-92. PubMed ID: 38156496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Cat S, TSP-1, IL-11, BNP and sST2 Diagnostic and Prognostic Value in Chronic Heart Failure.
    Xiang Y; Zhang Z; Xie C; Wang L; Wu Y; Zhan Y; Chen D
    Altern Ther Health Med; 2022 May; 28(4):55-59. PubMed ID: 35452416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Soluble Suppression of Tumorigenesis-2 (ST2) with Endothelial Function in Patients with Ischemic Heart Failure.
    Dimitropoulos S; Mystakidi VC; Oikonomou E; Siasos G; Tsigkou V; Athanasiou D; Gouliopoulos N; Bletsa E; Kalampogias A; Charalambous G; Tsioufis C; Vavuranakis M; Tousoulis D
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction.
    Cui Y; Qi X; Huang A; Li J; Hou W; Liu K
    Med Sci Monit; 2018 Jul; 24():5139-5146. PubMed ID: 30039808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy.
    Obradovic DM; Büttner P; Rommel KP; Blazek S; Loncar G; von Haehling S; von Roeder M; Lücke C; Gutberlet M; Thiele H; Lurz P; Besler C
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum parathyroid hormone levels predict hospitalization in outpatients of heart failure: a preliminary study].
    Wu GY; Zong GJ; Chen JK; Chen MQ; Xia Y; Wang X; Wang LL; Shi YC; Wang TX; Wang XY; Jin WD
    Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2205-8. PubMed ID: 24169329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure.
    Feola M; Aspromonte N; Canali C; Ceci V; Giovinazzo P; Milani L; Quarta G; Ricci R; Scardovi AB; Uslenghi E; Valle R
    Am J Cardiol; 2005 Sep; 96(5):705-9. PubMed ID: 16125500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.